

## Summary of EUCAST Steering Committee Meeting Birmingham, UK, 12-13 June 2008

### Attending

Dr Derek F.J. Brown	DB	Scientific Secretary	United Kingdom
Dr Rafael Cantón	RC	Clinical Data Co-ordinator	Spain
Prof Gunnar Kahlmeter	GK	Chairperson	Sweden
Dr Antti Hakanen	AH	EUCAST	Finland
Prof Alasdair P. MacGowan	AM	BSAC	United Kingdom
Dr Johan W. Mouton	JM	CRG	The Netherlands
Prof Claude-James Soussy	CS	CA-SFM	France
Prof Paul Tulkens	PT	EUCAST	Belgium

### Apologies

Prof Inga Odenholt	IO	SRGA	Sweden
Prof Arne Rodloff	AR	DIN	Germany
Dr Martin Steinbakk/Yngvar Tveten	MS/YT	NWGA	Norway

<b>1</b>	<b>Chairman's welcome</b> GK welcomed Prof Paul Tulkens and Prof Antti Hakanen as new representatives of the General Committee.
<b>2</b>	<b>Minutes of meeting of 22-23 April 2008</b> With minor corrections the minutes were accepted as a correct record.
<b>3</b>	<p><b>Matters arising from minutes of 22-23 April 2008</b> MIC distributions for <i>H. influenzae</i>, and quinupristin-dalfopristin MIC distributions for all relevant organisms are being sought.</p> <p>Export of data from the WHOnet program in a format to import into the EUCAST Excel spreadsheet is being investigated.</p> <p>Data on dosages and breakpoints for oral cephalosporins are being collected.</p> <p>Data on use of moxifloxacin for anaerobic intra-abdominal infections are being requested.</p> <p>MIC distributions for anaerobes will be added to the wild type MIC distributions website.</p> <p>References supporting tetracycline breakpoints for <i>N. gonorrhoeae</i> have been provided.</p> <p>The submission for extended indications for a tetracycline has been withdrawn.</p> <p>Questions related to a new cephalosporin are being followed up.</p> <p>Aspects of proposed penicillin breakpoints were discussed and the table updated.</p> <p>Breakpoints for a new glycopeptide have been proposed.</p> <p>The rationale document for a new quinolone is being prepared.</p>
<b>4</b>	<b>New drugs</b> The current status of several new agents was reviewed.
<b>5</b>	<b>Status of EUCAST documents</b> There was no change since the last meeting.
<b>6</b>	<b>Expert rules subcommittee</b> Preparation of a journal supplement continues and development of a computer program for application of the rules is being pursued.
<b>7</b>	<b>Antifungal susceptibility testing subcommittee</b> The voriconazole rationale document is completed and the proposed breakpoints will be sent for general consultation. The ISO committee on a broth microdilution method for yeasts has met.

8	<b>Anaerobe subcommittee</b> No new information.
9	<b>Penicillin breakpoints</b> The draft breakpoint table will be revised before release on the website.
10	<b>Breakpoints for viridans streptococci</b> Inclusion of the group as “other streptococci” was agreed and the need for breakpoints for different agents reviewed.
11	<b>Organisms/agents requiring breakpoints</b> Additional groups of organisms requiring breakpoint were reviewed and may include <i>C. difficile</i> , <i>H. pylori</i> , <i>Legionella</i> spp., <i>Listeria</i> spp. and Mycobacteria. The General Committee will be asked for their priorities and whether there are other groups of organisms or agents requiring EUCAST breakpoints.
12	<b>CLSI</b> No new information.
13	<b>ESCMID</b> For ECCMID 2009, proposals have been submitted for a workshop on problems in susceptibility testing and expert rules and for a symposium on aspects of implementation of EUCAST breakpoints. The practicality of a EUCAST Postgraduate Educational Workshop for 2009 will be investigated.
14	<b>EUCAST disk diffusion method</b> The development of a method based on the Kirby-Bauer approach with EUCAST breakpoints was supported and preliminary work will be done over the next few months. Some disk contents and the medium for fastidious organisms will need particular attention.
15	<b>ECDC</b> The proposal for a European Susceptibility Organisation was out and EUCAST, with ESCMID, would respond. A call for tenders for a disk diffusion method is likely to be issued in the autumn.
17	<b>EMA</b> A presentation to the Steering Committee on the EMA regulatory process is expected later this year.
18	<b>Oral cephalosporins</b> The draft table was reviewed. The draft breakpoints will be discussed again at the next meeting in September and will then be sent out for general comment.
19	<b>New quinolone</b> Proposed breakpoints were agreed.
20	<b>Review of glycopeptide breakpoints</b> Possible changes to breakpoints were discussed and proposals will be released for consultation.
21	<p><b>Any other business</b> Prof Inga Odenholt was thanked for her contributions to the work of the Steering Committee as this was her last meeting as representative of the SRGA.</p> <p>It was agreed to review colistin breakpoints for <i>Pseudomonas</i> and <i>Acinetobacter</i> in 2009.</p>
22	<p><b>Next meetings</b> 8-9 September 2008. Växjö, Sweden. 24-25 November 2008. Rome, Italy 26-27 January 2009, Madrid, Spain 19-20 May 2009. Helsinki, Finland (following ECCMID)</p>

Ratified summary of minutes of meeting 12-13 June 2008. Prepared by DB, GK and RC